Deciphera Pharmaceuticals, Inc.

NasdaqGS:DCPH Stock Report

Market Cap: US$1.2b

Deciphera Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Deciphera Pharmaceuticals's earnings have been declining at an average annual rate of -5.5%, while the Biotechs industry saw earnings growing at 14.5% annually. Revenues have been growing at an average rate of 46.1% per year.

Key information

-5.5%

Earnings growth rate

8.1%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate46.1%
Return on equity-55.6%
Net Margin-119.3%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Mar 13
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Dec 02
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?

Sep 25
Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Jul 26
Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Jun 22
Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S

May 08
Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Apr 10
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Dec 29
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Deciphera initiated at buy at Cowen on Qinlock growth, pipeline; sees 68% upside

Aug 29

Deciphera Pharmaceuticals Q2 2022 Earnings Preview

Aug 03

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully

Jul 29
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully

Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now

Feb 11

Deciphera Pharmaceuticals: The 75% Haircut Doesn't Seem Justified

Nov 22

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Aug 26
Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Deciphera Pharmaceuticals posts data from cancer studies at ASCO21

Jun 04

Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth

May 10
Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth

Growth Investors: Industry Analysts Just Upgraded Their Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Revenue Forecasts By 16%

Feb 11
Growth Investors: Industry Analysts Just Upgraded Their Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Revenue Forecasts By 16%

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Feb 05
Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Deciphera to expand geographic reach and clinical potential of ripretinib

Jan 11

Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Intrinsic Value Is Potentially 72% Above Its Share Price

Dec 15
Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Intrinsic Value Is Potentially 72% Above Its Share Price

Deciphera completes enrollment in late-stage study of ripretinib in GIST patients

Nov 30

Revenue & Expenses Breakdown
Beta

How Deciphera Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:DCPH Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 23163-1951360
30 Sep 23151-1941300
30 Jun 23144-1871260
31 Mar 23138-1821230
31 Dec 22134-1791200
30 Sep 22122-2211210
30 Jun 22109-2581270
31 Mar 22100-2861300
31 Dec 2196-3001320
30 Sep 2191-2741290
30 Jun 2184-2581240
31 Mar 2167-2551210
31 Dec 2042-2661140
30 Sep 2023-2711080
30 Jun 207-263960
31 Mar 2025-21876-36
31 Dec 1925-192660
30 Sep 1925-1574827
30 Jun 1925-1263648
31 Mar 190-12629102
31 Dec 180-100210
30 Sep 180-871971
30 Jun 180-751760
31 Mar 180-641451
31 Dec 170-501140
30 Sep 170-39930
30 Jun 170-33825
31 Mar 170-28722
31 Dec 160-26620

Quality Earnings: DCPH is currently unprofitable.

Growing Profit Margin: DCPH is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: DCPH is unprofitable, and losses have increased over the past 5 years at a rate of 5.5% per year.

Accelerating Growth: Unable to compare DCPH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DCPH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).


Return on Equity

High ROE: DCPH has a negative Return on Equity (-55.55%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.